mitonafide

Also Known As:

2-(2-(dimethylamino)ethyl)-5-nitro-1H-benz(de)isoquinoline-1,3(2H)-dione; 2-dimethylaminoethylbenzo(de)isoquinoline-1,3-dione hydrochloride; 5-nitro-2-(2-dimethylaminoethyl)benzo(de)isoquinoline-1,3-dione; M 4212; M-4212; N-(2-dimethylaminoethyl)-3-nitro-naphthalimide; N-(2-dimethylaminoethyl)-3-nitronaphthalimide; NSC 300288

Networked: 14 relevant articles (0 outcomes, 6 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Liang, Gui-Bin: 2 articles (01/2021 - 01/2020)
2.	Wei, Jian-Hua: 2 articles (01/2021 - 01/2020)
3.	Zhang, Ye: 2 articles (01/2021 - 01/2020)
4.	Bak, Andrzej: 1 article (03/2021)
5.	Fedoruk-Wyszomirska, Agnieszka: 1 article (03/2021)
6.	Giel-Pietraszuk, Małgorzata: 1 article (03/2021)
7.	Gurda-Woźna, Dorota: 1 article (03/2021)
8.	Kiliszek, Agnieszka: 1 article (03/2021)
9.	Kowalczyk, Aleksandra: 1 article (03/2021)
10.	Olejniczak, Agnieszka B: 1 article (03/2021)

Related Diseases

1.	Neoplasms (Cancer) 08/01/1992 - "Phase I study of mitonafide in solid tumors." 01/01/2020 - "MTT assay results showed that all these compounds exhibited obvious antiproliferative activity against SKOV3, HepG2, A549, T-24 and SMMC-7721 cancer cell lines, while compound 1a displayed the best antiproliferative activity against HepG2 and T-24 cell lines in comparison with mitonafide, with IC50 of 9.2 ± 1.8 and 4.133 ± 0.9 μM, respectively. " 01/01/1994 - "Eleven patients with solid tumors for whom effective therapy was not available entered a phase I study of mitonafide given as a short intravenous (i.v.) infusion daily for 3 consecutive days. " 01/01/2023 - "In particular, in vivo antitumor assay results revealed that bisnaphthalimide A6 exhibited potent anticancer efficiency in an MGC-803 xenograft tumor model, in comparison with mitonafide, and had lower toxicity than mono-naphthalimide A7. " 03/09/2021 - "We synthesized a series of novel 3-carboranyl-1,8-naphthalimide derivatives, mitonafide and pinafide analogs, using click chemistry, reductive amination and amidation reactions and investigated their in vitro effects on cytotoxicity, cell death, cell cycle, and the production of reactive oxygen species in a HepG2 cancer cell line. "
2.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/1996 - "Phase II study of mitonafide in non-small cell lung cancer (NSCLC)." 08/01/1992 - "This phase I Mitonafide study in non-small cell lung cancer using a 120-hour continuous infusion (120 h. " 08/01/1992 - "Phase I study of mitonafide in 120 hour continuous infusion in non-small cell lung cancer." 01/01/1996 - "Forty-nine patients with previously untreated non-small cell lung cancer (NSCLC) and at least one measurable site received Mitonafide as a 120-hour continuous (5 days) infusion every 3 weeks. "
3.	Colorectal Neoplasms (Colorectal Cancer) 01/01/1996 - "At the dose and schedule of administration used, Mitonafide is not active in colorectal cancer and induces severe myelotoxicity thus not deserving further studies in this indication." 01/01/1996 - "Phase II study of Mitonafide in advanced and relapsed colorectal cancer." 01/01/1996 - "This study investigated the antitumoral activity in colorectal cancer and toxicity of a 5-day continuous infusion of a new cytostatic agent, Mitonafide, that had previously shown to be neurotoxic when administered as a short daily x 5 days infusion. "
4.	Chromosome Aberrations (Chromosome Abnormalities) 06/01/1983 - "At concentrations of 0.01 and 1.0 microM, respectively, mitonafide increased the frequency of sister chromatid exchanges and chromosome aberrations in CHO cells. " 06/01/1983 - "Mitonafide induced DNA strand breaks and chromosome abnormalities in cultured cells." 06/01/1983 - "Induction of DNA strand breaks and chromosome abnormalities by an imide derivative of 3-nitro-1,8-naphthalic acid (mitonafide) in Chinese hamster ovary cells."
5.	Carcinoma (Carcinomatosis) 01/01/1980 - "Two of the most active compounds, M-4212 and M-12210, prevented the development of mouse Ehrlich ascites and rat Yoshida carcinoma. "

Related Drugs and Biologics

1.	amonafide
2.	Naphthalimides
3.	Antineoplastic Agents (Antineoplastics)
4.	Cytostatic Agents
5.	Imides
6.	DNA (Deoxyribonucleic Acid)
7.	pinafide
8.	Reactive Oxygen Species (Oxygen Radicals)
9.	RNA (Ribonucleic Acid)
10.	Lomustine (CCNU)

Related Therapies and Procedures

1.	Therapeutics